Fig. 1
From: Investigation of the efficacy of the short regimen for rifampicin-resistant TB from the STREAM trial
Summary of alternative secondary efficacy outcomes by treatment arm in MITT analysis population. Total length of bars is 100%; bars are centered at the cure dichotomy. (a) WHO end of treatment outcomes for rifampicin-resistant TB. (b) WHO outcomes modified to include post-treatment relapse. (c) TBNET MDR-TB outcomes [22]. (d) Modified WHO outcomes for short regimens [19]. (E) End of follow-up. Week 132 outcomes (week 132 outcomes: no culture after baseline is represented in the figure as “undeclared outcome”, culture positive at week 132 is represented as “treatment failed: bacteriological”, last culture positive prior to week 132 as “treatment failure: never converted” and last culture negative prior to week 132 as “lost to follow-up”)